Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution
Source: SeekingAlpha
2026-03-03 13:50:10 ET
The last time I spoke about Prothena Corporation plc ( PRTA ), it was in a Seeking Alpha article entitled " Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place ." I went over two of its main clinical programs, which were the use of monoclonal antibodies to treat patients with neurodegenerative disorders. One program involves the company partnering with Roche ( RHHBY ) to evaluate the use of anti-alpha-synuclein antibody prasinezumab for the treatment of patients with early-stage Parkinson's Disease [PD] in the ongoing phase 3 PARAISO study....
Read the full article on Seeking Alpha
For further details see:
Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution
Prothena Corporation plc
NASDAQ: PRTA
PRTA Trading
1.92% G/L:
$10.08 Last:
347,077 Volume:
$10.21 Open:
PRTA Latest News
March 09, 2026 04:05:00 pm
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
PRTA Stock Data
$486,084,737
38,757,587
1.22%
55
N/A
Biotechnology & Life Sciences
Healthcare
IE
Dublin 2
